Immunotherapy produces durable responses in dMMR/MSI-H metastatic CRC patients with poor performance status

◆ TRIAL DATA

Research shows that patients with deficient mismatch repair or high microsatellite instability can benefit from immunotherapy even when they have poor performance status, a group often excluded from clinical trials. (Clinical Colorectal Cancer)